World Bank Report Accuses Indian Drug Makers Of Bid-Rigging
This article was originally published in PharmAsia News
A World Bank investigation accuses Nestor Pharmaceuticals and Pure Pharma, both Indian drug makers, of rigging bids to gain contracts from government agencies. The report says the drug makers, after winning the contracts, failed to deliver the drug quantities required and diluted those they did supply. The Indian government had blacklisted both companies in 2006 and the companies have filed suit for that action. The report said the activities occurred in three projects, including one aimed at controlling tuberculosis and malaria. (Click here for more
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.